Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab After Chemoradiotherapy in NSCLC

This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.

https://ift.tt/2BfvMlk